The efficacy of delafloxacin was noninferior compared with moxifloxacin for treatment of community-aquired bacterial pneumonia (CABP) in patients with diabetes. The results of this study was presented at ID Week 2019, held October 2 to October 6, 2019, in Washington, DC.
Adults with CABP with at least 2 presenting symptoms were randomly assigned in a 1:1 ratio to treatment with either delafloxacin or moxifloxacin for 5 to 10 days. Patients received a minimum of 3 days of intravenous treatment followed by oral treatment for the remaining days. Clinical success was defined as a complete or near resolution of signs and symptoms and no further antibiotics needed.
A total of 131 patients were included in the study; 59% were male and the mean age was 66 years. Bacterial pathogens were identified in 59% of patients at baseline. Patients received treatment for approximately 8.5 days, and results showed that early clinical response occurred in 90% of patients with diabetes who received delafloxacin compared with 88.5% of those who received moxifloxacin. Further, clinical success at test of cure was 87.1% in patients who received delafloxacin vs 86.9% of those who received moxifloxacin.
A total of 18.6% taking delafloxacin and 11.7% taking moxifloxacin had at least 1 treatment-related adverse event, the most common being gastrointestinal-related. A total of 3 delafloxacin and 2 moxifloxacin patients died during the study, though investigators reported this was unrelated to treatment. No patients experienced hypoglycemia
“[Delafloxacin] appears effective and well tolerated in patients with diabetes and CABP,” the authors concluded.
Kaidashev I, Nitu M, Popescu M, et al. Treatment of community acquired bacterial pneumonia (CABP) in patients with diabetes: outcomes from a global phase 3 study of selafloxacin (DLX). Presented at: IDWeek 2019; October 2-6, 2019; Washington DC. Poster 222.
This article originally appeared on Infectious Disease Advisor